Sodium glycerophosphate

Sodium glycerophosphate
Clinical data
Trade names	Glycophos
AHFS/Drugs.com	Professional Drug Facts
Pregnancy; category	AU: Exempt; ;
Routes of; administration	Intravenous infusion
ATC code	B05XA14 (WHO) ;
Legal status
Legal status	AU: Unscheduled;
Identifiers
	IUPAC name disodium 3-(phosphonooxy)propane-1,2-diol;
CAS Number	1334-74-3 ; 55073-41-1 ;
PubChem CID	22251426;
DrugBank	DB09561;
ChemSpider	14071;
UNII	YP1H63LJ2K; RCS9EQ01V4;
KEGG	D10489;
ChEMBL	ChEMBL3040581;
Chemical and physical data
Formula	C3H7Na2O6P
Molar mass	216.036 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	98 to 100 °C (208 to 212 °F)
Solubility in water	very soluble
	SMILES [Na+].[Na+].OCC(O)COP([O-])([O-])=O;
	InChI InChI=1S/C3H9O6P.2Na/c4-1-3(5)2-9-10(6,7)8;;/h3-5H,1-2H2,(H2,6,7,8);;/q;2*+1/p-2; Key:GEKBIENFFVFKRG-UHFFFAOYSA-L; Key:OFNNKPAERNWEDD-UHFFFAOYSA-L;

Sodium glycerophosphate, sold under the brand name Glycophos, is a medication used to supplement phosphate.^[3]^[4] It is administered via intravenous infusion.^[3]^[4]

Sodium glycerophosphate is an organic phosphate salt.^[3]^[4]

It was approved for medical use in Australia in November 2019.^[5]^[3]^[6]

It is an unapproved medication in the United States that was used as a substitute for inorganic phosphate during a drug shortage.^[4]

Chemistry

The substance is a mixture of disodium glycerol 1- and 2-phosphates, which have different amounts of water of crystallization; the total amount is 5+1⁄2 H₂O per glycerol phosphate molecule. It is a white to off-white powder which may or may not be crystalline, has no discernible odor and tastes salty. It melts at 98 to 100 °C (208 to 212 °F) and decomposes at 130 °C (266 °F). Aqueous solutions have a pH of about 9.5.^[7]

References

^ "Glycophos APMDS". Therapeutic Goods Administration (TGA). 26 May 2022. Retrieved 10 March 2024.
^ "Australian Public Assessment Report for Sodium glycerophosphate (as hydrate)" (PDF). Therapeutic Goods Administration (TGA).
^ ^a ^b ^c ^d "ARTG Entry:312021 Glycophos Product Information" (PDF). Therapeutic Goods Administration (TGA). Retrieved 23 August 2020.
^ ^a ^b ^c ^d "Glycophos- sodium glycolate injection, solution". DailyMed. 16 January 2019. Retrieved 23 August 2020.
^ "Glycophos Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). Retrieved 23 August 2020.
^ "Summary for ARTG Entry:312021 Glycophos sodium glycerophosphate (as hydrate) 4.32 g/20 mL concentrated solution for injection ampoule". Therapeutic Goods Administration (TGA). Archived from the original on 18 April 2021. Retrieved 23 August 2020.
^ Hagers Handbuch der pharmazeutischen Praxis (in German). Vol. VI.A (4th ed.). Springer. 15 August 1977. pp. 91–92. ISBN 3-540-05123-6.

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.

[1] "Glycophos APMDS". Therapeutic Goods Administration (TGA). 26 May 2022. Retrieved 10 March 2024.

[2] "Australian Public Assessment Report for Sodium glycerophosphate (as hydrate)" (PDF). Therapeutic Goods Administration (TGA).

[TGA_PI-3] "ARTG Entry:312021 Glycophos Product Information" (PDF). Therapeutic Goods Administration (TGA). Retrieved 23 August 2020.

[Glycophos_FDA_label-4] "Glycophos- sodium glycolate injection, solution". DailyMed. 16 January 2019. Retrieved 23 August 2020.

[Glycophos_APMDS-5] "Glycophos Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). Retrieved 23 August 2020.

[6] "Summary for ARTG Entry:312021 Glycophos sodium glycerophosphate (as hydrate) 4.32 g/20 mL concentrated solution for injection ampoule". Therapeutic Goods Administration (TGA). Archived from the original on 18 April 2021. Retrieved 23 August 2020.

[7] Hagers Handbuch der pharmazeutischen Praxis (in German). Vol. VI.A (4th ed.). Springer. 15 August 1977. pp. 91–92. ISBN 3-540-05123-6.

[3]

[4]

[1]

[2]

[5]

[6]

[7]